Go Pro
NYSEAMERICAN:PHGE

BiomX Q4 2025 Earnings Report

BiomX logo
$1.85 0.00 (0.00%)
As of 09/10/2026

BiomX EPS Results

Actual EPS
$69.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BiomX Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BiomX Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Thursday, February 19, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

BiomX's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

BiomX Earnings Headlines

BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 83.3% in August
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More BiomX Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BiomX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BiomX and other key companies, straight to your email.

About BiomX

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company developing precision therapies that target harmful bacteria while seeking to preserve beneficial components of the microbiome. The company’s platform uses bacteriophages, naturally occurring viruses that selectively infect and destroy specific bacterial strains, to address diseases associated with bacterial imbalances or persistent infections.

BiomX’s development programs have included BX004, an inhaled phage therapy designed to target Pseudomonas aeruginosa infections associated with cystic fibrosis, and BX211, a candidate intended to target bacteria implicated in ulcerative colitis. The company has also worked on phage-based approaches for other chronic and infectious diseases, including programs focused on identifying and eliminating disease-associated bacterial strains.

BiomX was founded in Israel and has conducted research and clinical development activities in Israel, the United States and other international locations. The company’s operations have been supported by collaborations with academic and clinical institutions as it advances its microbiome-focused therapeutics. Jonathan Solomon has served as chief executive officer and has been associated with the company’s development of targeted bacteriophage treatments.

View BiomX Profile